drugset / Trial / NCT00003926

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

NCT00003926

Phase 1 Terminated 13 enrolled Masonic Cancer Center, University of Minnesota
Non-randomizedParallel-groupOpen-labelSupportive care

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of high-dose chemotherapy. PURPOSE: Phase I trial to study the effectiveness of amifostine in protecting from the side effects of peripheral stem cell transplantation in treating patients who have high-risk or relapsed solid tumors.

Timeline

Start
1998-11
Primary completion
2002-08
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Subject amifostine Unknown Intravenous
Background Busulfan Small molecule Oral
Background Melphalan Small molecule Intravenous
Background Thiotepa Other / unclassified Intravenous
Background filgrastim Protein / enzyme biologic Intravenous